Clinical Trial Update: Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating thalidomide, lenalidomide, and rituximab for previously treated Waldenström macroglobulinemia was terminated, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)
• Thalomid (thalidomide)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: TERMINATED | Results posted: 2017-04-07